MedTrace Logo

Immunological Comparison of AIT and SCIT Immunotherapy Against Grass Pollen

NCT01889875 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-07-01

No results posted yet for this study

Summary

Treatment of pollen allergies can be roughly divided into symptomatic treatment (e.g. antihistamines, steroids) and potentially curative immunotherapy. Immunotherapy can be delivered using subcutaneous or oral (mucosal) routes, with similar clinical outcome. The study seeks to compare immunological changes during subcutaneous (SCIT) and sublingual tablet (AIT) immunotherapy of grass pollen allergy (hayfever).

Conditions

  • Allergic Rhinitis Due to Grass Pollens

Interventions

DRUG

ALK Grazax 75,000 SQ-T "Phleum pratense"

DRUG

ALK AluTard 225 "Phleum pratense"

Sponsors & Collaborators

  • ALK-Abelló A/S

    collaborator INDUSTRY

  • Bispebjerg Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Denmark

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01889875 on ClinicalTrials.gov